➡️ Language: English
➡️ Duration: 31 min
➡️ Presenter: Prof. ELIZABETH BRAUNLIN, University of Minnesota, USA
Learning Objectives: (1) Develop an understanding of the cardiac manifestations of MPS (2) Understand the methods of assessing the cardiac manifestations of MPS (3) Understand the effects of ERT and HCT on the cardiac manifestations of MPS.
Dr Braunlin is a Professor of Pediatrics in the Division of Pediatric Cardiology and Director of the Pediatric Cardiology Fellowship Program. She received her M.D. from the University of Minnesota. Dr Braunlin completed her residency in Pediatrics at The Children’s Hospital Medical Center in Boston and a fellowship in Pediatric Cardiology at the University of Minnesota. Dr Braunlin completed her PhD in Physiology at the University of Minnesota. She joined the faculty at the University of Minnesota in 1983. She is board certified in Pediatrics and Pediatric Cardiology. Dr Braunlin’s clinical interests are prevention and treatment of post-transplant lymphoproliferative disease (PTLD) after cardiac transplantation; the long term cardiac follow-up of individuals with mucopolysaccharidoses after marrow transplantation or enzyme replacement therapy; and prevention and management of cardiac failure in individuals with various forms of muscular dystrophy. Her basic research interest involves an investigation by cardiac ultrasound and histopathology of murine models of mucopolysaccharidoses both before and after novel therapies aimed at correction.
Important Note: The information provided on this session is intended and designed for use by healthcare professionals with an interest in metabolic diseases, MPS and alpha-mannosidosis. All session viewers are required to register for the selected webinar before accessing the content. Content and views shared are solely those of the speaker.
The free-to-attend online course has been designed to help specialists and general paediatricians to reduce delay in the referral and diagnosis of patients with suspected MPS and alpha-mannosidosis, as well as improving the quality of patient’s lives who have already been diagnosed. On-time diagnosis is crucial for access to treatment and clinical trials, disease management and to access the proper care services at the earliest of the disease possible.
The course is an MPS Europe project in partnership with MetabERN and the Excellence in Pediatrics with the support of Abeona, Biomarin, Chiesi, Orchard Therapeutics, Regenxbio, Sanofi Genzyme, Takeda, and Ultragenyx. All modules of the course are independently organised by EIP in terms of content, topics and speakers appointed.